Chronic Urticaria Or Hives - Pipeline Insight, 2018
SKU ID : DEL-11679826 | Publishing Date : 01-Jan-2018 | No. of pages : 50
Detailed TOC of Chronic Urticaria Or Hives - Pipeline Insight, 2018
1. Report Introduction2. Chronic Urticaria Or Hives Overview
3. Pipeline Therapeutics
• An Overview of Pipeline Products for Chronic Urticaria Or Hives
4. Comparative Analysis
5. Products in Clinical Stage
5.1 Drug Name : Company Name
• Product Description
• Research and Development
• Product Development Activities
6. Products in Pre-Clinical and Discovery Stage
6.1 Drug Name : Company Name
• Product Description
• Research and Development
• Product Development Activities
7. Therapeutic Assessment
• Assessment by Route of Administration
• Assessment by Stage and Route of Administration
• Assessment by Molecule Type
• Assessment by Stage and Molecule Type
8. Inactive Products
8.1 Drug Name : Company Name
• Product Description
• Research and Development
• Product Development Activities
Appendix
Report Methodology
Consulting Services
Disclaimer
About DelveInsight
List of Figures, Tables and Charts Available in Chronic Urticaria Or Hives - Pipeline Insight, 2018
Table 1: Total Products for Chronic Urticaria Or HivesTable 2: Products in Clinical Stage
Table 3: Products in Non-clinical Stage
Table 4: Assessment by Route of Administration
Table 5: Assessment by Stage and Route of Administration
Table 6: Assessment by Molecule Type
Table 7: Assessment by Stage and Molecule Type
Table 8: Inactive Products
Figure 1: Total Products for Chronic Urticaria Or Hives
Figure 2: Products in Clinical Stage
Figure 3: Products in Non-clinical Stage
Figure 4: Assessment by Route of Administration
Figure 5: Assessment by Stage and Route of Administration
Figure 6: Assessment by Molecule Type
Figure 7: Assessment by Stage and Molecule Type
Figure 8: Inactive Products
Keyplayers in Chronic Urticaria Or Hives - Pipeline Insight, 2018
GlaxoSmithKlineNovartis Pharmaceuticals
Hoffmann-La Roche
Schering-Plough
UCB
Pfizer
Faes Farma
Bristol-Myers Squibb
& list continues...